FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033997413> ?p ?o ?g. }

• W3033997413 endingPage "e83" @default.
• W3033997413 startingPage "e74" @default.
• W3033997413 abstract "The Xpert MTB/RIF (Xpert) assay is used globally to rapidly diagnose tuberculosis and resistance to rifampicin. We investigated the frequency and predictors of false-positive findings of rifampicin resistance with Xpert.We did a prospective, observational study of individuals who were enrolled in a Rwandan nationwide diagnostic cohort study (DIAMA trial; NCT03303963). We included patients identified to have rifampicin resistance on initial Xpert testing. We did a repeat Xpert assay and used rpoB Sanger and deep sequencing alongside phenotypic drug susceptibility testing (pDST) to ascertain final rifampicin susceptibility status, with any (hetero)resistant result overriding. We used multivariable logistic regression to assess predictors of false rifampicin resistance on initial Xpert testing, adjusted for HIV status, tuberculosis treatment history, initial Xpert semi-quantitative bacillary load, and initial Xpert probe.Between May 4, 2017, and April 30, 2019, 175 people were identified with rifampicin resistance at initial Xpert testing, of whom 154 (88%) underwent repeat Xpert assay. 54 (35%) patients were confirmed as rifampicin resistant on repeat testing and 100 (65%) were not confirmed with resistance. After further testing and sequencing, 121 (79%) of 154 patients had a final confirmed status for rifampicin susceptibility. 57 (47%) of 121 patients were confirmed to have a false rifampicin resistance result and 64 (53%) had true rifampicin resistance. A high pretest probability of rifampicin resistance did not decrease the odds of false rifampicin resistance (adjusted odds ratio [aOR] 6·0, 95% CI 1·0-35·0, for new tuberculosis patients vs patients who needed retreatment). Ten (16%) of the 64 patients with true rifampicin resistance did not have confirmed rifampicin resistance on repeat Xpert testing, of whom four had heteroresistance. Of 63 patients with a very low bacillary load on Xpert testing, 54 (86%) were falsely diagnosed with rifampicin-resistant tuberculosis. Having a very low bacillary load on Xpert testing was strongly associated with false rifampicin resistance at the initial Xpert assay (aOR 63·6, 95% CI 9·9-410·4).The Xpert testing algorithm should include an assessment of bacillary load and retesting in case rifampicin resistance is detected on a paucibacillary sputum sample. Only when rifampicin resistance has been confirmed on repeat testing should multidrug-resistant tuberculosis treatment be started. When rifampicin resistance has not been confirmed on repeat testing, we propose that patients should be given first-line anti-tuberculosis drugs and monitored closely during treatment, including by baseline culture, pDST, and further Xpert testing.The European & Developing Countries Clinical Trials Partnership 2 programme, and Belgian Directorate General for Development Cooperation." @default.
• W3033997413 created "2020-06-12" @default.
• W3033997413 creator A5007779583 @default.
• W3033997413 creator A5013814026 @default.
• W3033997413 creator A5014839628 @default.
• W3033997413 creator A5033438385 @default.
• W3033997413 creator A5044411310 @default.
• W3033997413 creator A5045845191 @default.
• W3033997413 creator A5047935595 @default.
• W3033997413 creator A5050349258 @default.
• W3033997413 creator A5055461864 @default.
• W3033997413 creator A5055729664 @default.
• W3033997413 creator A5058169462 @default.
• W3033997413 creator A5063612923 @default.
• W3033997413 creator A5065124552 @default.
• W3033997413 creator A5069490240 @default.
• W3033997413 creator A5074102154 @default.
• W3033997413 creator A5076621207 @default.
• W3033997413 creator A5078144985 @default.
• W3033997413 creator A5084505437 @default.
• W3033997413 creator A5089013920 @default.
• W3033997413 date "2020-06-01" @default.
• W3033997413 modified "2023-10-13" @default.
• W3033997413 title "Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda" @default.
• W3033997413 cites W2069473179 @default.
• W3033997413 cites W2103356125 @default.
• W3033997413 cites W2121562380 @default.
• W3033997413 cites W2123463403 @default.
• W3033997413 cites W2132658179 @default.
• W3033997413 cites W2154326381 @default.
• W3033997413 cites W2157429822 @default.
• W3033997413 cites W2163683100 @default.
• W3033997413 cites W2280180791 @default.
• W3033997413 cites W2293641450 @default.
• W3033997413 cites W2294285679 @default.
• W3033997413 cites W2556567056 @default.
• W3033997413 cites W2667839856 @default.
• W3033997413 cites W2753668595 @default.
• W3033997413 cites W2794372577 @default.
• W3033997413 cites W2800888530 @default.
• W3033997413 cites W2885516461 @default.
• W3033997413 cites W2895910368 @default.
• W3033997413 cites W2901029329 @default.
• W3033997413 cites W2951160681 @default.
• W3033997413 cites W2973279882 @default.
• W3033997413 cites W3010833257 @default.
• W3033997413 cites W3013159759 @default.
• W3033997413 cites W3024982053 @default.
• W3033997413 doi "https://doi.org/10.1016/s2666-5247(20)30007-0" @default.
• W3033997413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35544156" @default.
• W3033997413 hasPublicationYear "2020" @default.
• W3033997413 type Work @default.
• W3033997413 sameAs 3033997413 @default.
• W3033997413 citedByCount "32" @default.
• W3033997413 countsByYear W30339974132020 @default.
• W3033997413 countsByYear W30339974132021 @default.
• W3033997413 countsByYear W30339974132022 @default.
• W3033997413 countsByYear W30339974132023 @default.
• W3033997413 crossrefType "journal-article" @default.
• W3033997413 hasAuthorship W3033997413A5007779583 @default.
• W3033997413 hasAuthorship W3033997413A5013814026 @default.
• W3033997413 hasAuthorship W3033997413A5014839628 @default.
• W3033997413 hasAuthorship W3033997413A5033438385 @default.
• W3033997413 hasAuthorship W3033997413A5044411310 @default.
• W3033997413 hasAuthorship W3033997413A5045845191 @default.
• W3033997413 hasAuthorship W3033997413A5047935595 @default.
• W3033997413 hasAuthorship W3033997413A5050349258 @default.
• W3033997413 hasAuthorship W3033997413A5055461864 @default.
• W3033997413 hasAuthorship W3033997413A5055729664 @default.
• W3033997413 hasAuthorship W3033997413A5058169462 @default.
• W3033997413 hasAuthorship W3033997413A5063612923 @default.
• W3033997413 hasAuthorship W3033997413A5065124552 @default.
• W3033997413 hasAuthorship W3033997413A5069490240 @default.
• W3033997413 hasAuthorship W3033997413A5074102154 @default.
• W3033997413 hasAuthorship W3033997413A5076621207 @default.
• W3033997413 hasAuthorship W3033997413A5078144985 @default.
• W3033997413 hasAuthorship W3033997413A5084505437 @default.
• W3033997413 hasAuthorship W3033997413A5089013920 @default.
• W3033997413 hasBestOaLocation W30339974131 @default.
• W3033997413 hasConcept C114851261 @default.
• W3033997413 hasConcept C126322002 @default.
• W3033997413 hasConcept C142724271 @default.
• W3033997413 hasConcept C151956035 @default.
• W3033997413 hasConcept C156957248 @default.
• W3033997413 hasConcept C188816634 @default.
• W3033997413 hasConcept C23131810 @default.
• W3033997413 hasConcept C2777975735 @default.
• W3033997413 hasConcept C2778340795 @default.
• W3033997413 hasConcept C2778607973 @default.
• W3033997413 hasConcept C2781069245 @default.
• W3033997413 hasConcept C71924100 @default.
• W3033997413 hasConcept C86803240 @default.
• W3033997413 hasConcept C89423630 @default.
• W3033997413 hasConceptScore W3033997413C114851261 @default.
• W3033997413 hasConceptScore W3033997413C126322002 @default.
• W3033997413 hasConceptScore W3033997413C142724271 @default.
• W3033997413 hasConceptScore W3033997413C151956035 @default.
• W3033997413 hasConceptScore W3033997413C156957248 @default.

• next